Each Rare Disease Patient Is Unique. Your Development Strategy Should Be Too.
For rare disease patients, each day that passes without a clear path forward is another day spent without hope. At Camargo, we understand the added burden these diseases have on the lives of patients and their families, as well as the obstacles your rare disease development programs face. Through the combination of our unrivaled scientific and regulatory experience and customized research and development strategies, we accelerate your program’s pathway to approval — and ultimately to patients who need hope.
Camargo has supported the development of 65+ orphan products. Recent projects include:
- FDA and EMA Orphan Designation Requests
- Rare Pediatric Disease Designation Requests
- Nonclinical program execution through Camargo Research Group